<DOC>
	<DOCNO>NCT01437007</DOCNO>
	<brief_summary>Background : Cancer liver start liver ( e.g. , primary liver cancer hepatocellular cancer ) spread liver cancer part body ( e.g . colon , pancreas , gastric , breast , ovarian , esophageal cancer , cancer metastasis liver . ) People tumor remove surgery live long whose cancer remove . Chemotherapy shrink tumor liver , also help people live long , sometimes chemotherapy shrink tumor enough remove surgery . However , chemotherapy drug work well tumor liver . In study test new drug , TKM-080301 , give directly cancer blood supply liver circulation , see cause tumor shrink . Objectives : - To test safety effectiveness TKM-080301 cancer liver respond standard treatment . Eligibility : - Individuals least 18 year age inoperable cancer start spread liver . Design : - Participants screen medical history physical exam . They also blood test , image study . - Participants liver angiogram ( type X-ray study ) look blood flow liver place catheter delivery TKM080301 . - Participants single dose TKM-080301 give directly liver . After drug give , catheter remove . They frequent blood test keep diary record side effect . - Participants may two dos , dose give 2 week apart . { Before dose , participant another angiogram catheter placement . } They may also liver biopsy study tumor . - Two week third treatment ( one full course ) , participant physical exam , blood test , image study . If tumor shrinking , may three course study drug . - Participants follow visit every 3 month 2 year last course every 6 month require .</brief_summary>
	<brief_title>TKM 080301 Primary Secondary Liver Cancer</brief_title>
	<detailed_description>BACKGROUND : - Metastatic liver disease life-limiting factor patient variety cancer . For unresectable liver metastasis , 5-year survival &lt; 5 % . - For select histology 5-year survival resectable hepatic metastasis range 20-60 % , suggest control liver metastasis could result prolonged survival . - Phase I III trial show Hepatic Arterial Infusion ( HAI ) safe . However , agent use thus far HAI limit efficacy . - TKM-080301 lipid nanoparticle ( LNP ) formulation contain siRNA PLK1 ( polo-like kinase-1 ) gene product . More specifically , TKM-080301 type LNP formulation , refer SNALP ( Stable Nucleic Acid Lipid Particles ) . PLK1 validate molecular target prognostic factor variety cancer . Inhibition PLK1 activity proliferate cancer cell rapidly induces mitotic arrest apoptosis . - This study offer HAI TKM-080301 patient unresectable and/or life threaten primary liver cancer liver metastasis . OBJECTIVES : Primary Objective : - To evaluate feasibility administer TKM-080301 via HAI characterize pharmacokinetics ( PK ) pharmacodynamics TKM-080301 administered HAI . Secondary Objectives : - To establish maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) TKM-080301 . - To evaluate response rate use RECIST , PET EASL criterion . - To evaluate conversion rate unresectable resectable disease . ELIGIBILITY : - Patients unresectable colorectal , pancreas , gastric , breast , ovarian esophageal cancer hepatic metastasis ; primary liver cancer patient demonstrate progressive disease follow standard care treatment . - 18 year old great ECOG 0-2 - Laboratory physical examination parameter within acceptable limit standard practice guideline prior surgery chemotherapy . DESIGN : - This dose escalation phase-I study test HAI TKM-080301 patient unresectable colorectal , pancreas , gastric , breast , ovarian esophageal cancer hepatic metastasis , primary liver cancer . - Up 54 patient meet eligibility criterion receive HAI TKM-080301 . - Initial dose 4 mg/m ( 2 ) ; treatment give every 2 week 12 dos . - Patients evaluate every 6 week . Patients whose tumor become resectable offered option ; patient show progressive disease take treatment . All patient follow survival .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Histologically cytologically confirm colorectal , pancreas , gastric , breast , ovarian esophageal cancer hepatic metastasis , primary liver cancer ( Hepatocellular carcinoma Cholangiocarcinoma ) . 2 . Hepatic disease must measurable per RECIST Criteria ( version 1.1 ) . 3 . Hepatic disease deem unresectable per standard care criterion . Note : Evidence limit unresectable extrahepatic disease preoperative radiological study acceptable lifelimiting component progressive disease liver . 4 . All patient must fail respond standard regimen therapy know provide clinical benefit . For example : Patients metastatic colorectal cancer must receive 5FU leucovorin combination either oxaliplatin and/or irinotecan , since level 1 evidence support increase survival regimen , compare 5FU leucovorin alone . Patients hepatocellular carcinoma must receive sorafenib , since level 1 evidence support increase survival . 5 . Greater equal 18 year age 6 . Must able understand sign Informed Consent Document 7 . Clinical performance status ECOG le equal 2 8 . Life expectancy greater/equal two month 9 . Patients gender must willing practice birth control four month receive chemotherapy 10 . Hematology : Absolute neutrophil count great equal 1500/mm ( 3 ) without support filgrastim . Platelet count great equal 100,000/mm ( 3 ) . Hemoglobin great equal 9.0 g/dl . 11 . Chemistry : Serum ALT/AST less equal 2.5 time upper limit normal . Serum Albumin great equal 3.0 g/dL Serum creatinine less equal 1.5 time ULN unless measure creatinine clearance great 60 mL/min/1.73 ( 2 ) Total bilirubin less equal 1.2 mg/dl 12. International Normalized Ratio ( INR ) less equal 1.5 13 . Seronegative HIV antibody 14 . No chemotherapy investigational drug within 4 week treatment 15 . LVEF great equal 50 percent 16 . QT/QTc interval le 450 m EXCLUSION CRITERIA : 1 . Any known brain metastasis ( prior current regardless treatment status ) 2 . Women childbearing potential pregnant breastfeeding , potentially dangerous effect chemotherapy fetus infant . 3 . Active systemic infection , coagulation disorder major medical illness cardiovascular , respiratory immune system , recent myocardial infarction heart failure ( within 6 month enrollment ) . 4 . NYHA great equal 2 5 . Childs B C cirrhosis evidence severe portal hypertension history , endoscopy , radiologic study 6 . Weight le 40 kg 7 . Significant ascites , great 1000cc absence peritoneal disease 8 . Concomitant medical problem would place patient unacceptable risk procedure/drug 9 . Patient know hypersensitivity previous severe reaction oligonucleotideor lipidbased product , include liposomal drug product ( e.g . Doxil ) phospholipidbased product ( parenteral nutrition , Intralipid ) 10 . Discretion PI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 9, 2012</verification_date>
	<keyword>SNALP</keyword>
	<keyword>Regional Therapy</keyword>
	<keyword>Stage IV Disease</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Liver Metastases</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Stomach Cancer</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Liver Cancer</keyword>
</DOC>